Literature DB >> 19901260

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation.

Pedro Farinha1, Abdulwahab Al-Tourah, Karamjit Gill, Richard Klasa, Joseph M Connors, Randy D Gascoyne.   

Abstract

Previous studies of follicular lymphoma (FL) patients treated heterogeneously have suggested that decreased numbers of regulatory T cells correlates with improved survival. We studied advanced-stage FL patients from a single institution phase 2 trial. All patients were treated uniformly with multiagent chemotherapy and radiation. Tissue microarrays were constructed using diagnostic biopsies available in 105 patients and stained with CD4, CD8, CD25, and forkhead/winged helix transcription factor 3 (FOXP3) antibodies. Both cell content and cell distribution were evaluated. For all antibodies, there were cases with a predominant intrafollicular or perifollicular localization of cells (follicular pattern) while others displayed a diffuse pattern. The median follow-up of living patients was 17.1 years. The International Prognostic Index score predicted overall survival (OS; P = .004) but not risk of transformation (RT). Cell content did not impact survival, while immunoarchitectural patterns of CD4/CD8 were significant for progression-free survival (PFS; P = .056), CD25 for both PFS and OS (P = .002 and P = .024, respectively), and FOXP3(+) predicted PFS, OS, and RT (P = .001, P < .001 and p = .002, respectively). A Cox multivariate model showed both International Prognostic Index score and FOXP3(+) pattern were independent predictors of OS (P = .008 and P < .001, respectively), while only FOXP3(+) pattern predicted RT (P = .004). We conclude that FOXP3(+) cell distribution significantly predicts survival and RT in FL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19901260     DOI: 10.1182/blood-2009-07-235598

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  70 in total

1.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

2.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

Review 3.  Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Authors:  Nishitha Reddy; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

4.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

Review 5.  Cancer immunotherapy--revisited.

Authors:  W Joost Lesterhuis; John B A G Haanen; Cornelis J A Punt
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

Review 6.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

7.  Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Authors:  Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

8.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 9.  Unmet needs in the first-line treatment of follicular lymphoma.

Authors:  C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

Review 10.  Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Authors:  Fabienne McClanahan; Thomas G Sharp; John G Gribben
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.